AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23852296 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day mifepristone for 3 months
Number of subjects: 143
Study 21358850 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 16
Study 19595055 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 83
Study 19595055 — intervention group
Group type: EXPERIMENTAL
Intervention: IGR subjects
Number of subjects: 83
Study 19595055 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 83
Study 19595055 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE
Number of subjects: 83
Study 16496864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional analysis
Number of subjects: 0
Study 16496864 — intervention group
Group type: COMPARATOR
Intervention: Traditional math method
Number of subjects: 0
Study 15275754 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.8% hypertonic saline (0.5 ml in each side for each bilateral injection)
Number of subjects: 21
Study 15275754 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 21
Study 10190658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (three times daily for 6 weeks)
Number of subjects: 10
Study 10190658 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone (once daily)
Number of subjects: 10
Study 10190658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily for 1 week)
Number of subjects: 10
Study 7762498 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments
Number of subjects: 28
Study 7762498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 28
Study 7762498 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 28
Study 7762498 — intervention group
Group type: COMPARATOR
Intervention: No drug therapy
Number of subjects: 28
Study 7762498 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP apheresis
Number of subjects: 28
Study 7762498 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP treatments
Number of subjects: 28
Study 2082485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 100 mg t.i.d. plus warfarin (Study 1)
Number of subjects: 250
Study 2082485 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release capsules of dipyridamole plus warfarin (Study 2)
Number of subjects: 250
Study 2082485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet form dipyridamole plus warfarin (Study 2)
Number of subjects: 250
Study 371902 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg metoprolol once daily
Number of subjects: 32
Study 371902 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg metoprolol once daily
Number of subjects: 32
Study 371902 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg and 300 mg metoprolol
Number of subjects: 32
Study 371902 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 32
Study 30706788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 & 8 mg)
Number of subjects: 96
Study 30706788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 28061756 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group exposed to photos and text of active peers, N = 10
Number of subjects: 47
Study 28061756 — intervention group
Group type: COMPARATOR
Intervention: Control group exposed to photos and text of inactive peers, N = 11
Number of subjects: 47
Study 28061756 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 47
Study 28061756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 24969380 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (target dose: 24 mg)
Number of subjects: 100
Study 24969380 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (target dose: 1.5 mg)
Number of subjects: 100
Study 22547439 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 207
Study 22547439 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 207
Study 20183659 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiando a Ninos Activos (GANA)
Number of subjects: 58
Study 20183659 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (PCIT)
Number of subjects: 58
Study 20183659 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 58
Study 17442158 — intervention group
Group type: EXPERIMENTAL
Intervention: HS‐LASEK (5% sodium chloride)
Number of subjects: 48
Study 17442158 — intervention group
Group type: COMPARATOR
Intervention: A‐LASEK (20% alcohol)
Number of subjects: 48
Study 15735116 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m(2), days 1 and 4), epirubicin (90 mg/m(2), day 1), and paclitaxel (175 mg/m(2), day 1)
Number of subjects: 259
Study 15735116 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (500 mg/m(2), day 1), epirubicin (90 mg/m(2), day 1), and cyclophosphamide (500 mg/m(2), day 1)
Number of subjects: 259
Study 15735116 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, epirubicin, and paclitaxel (GET)
Number of subjects: 259
Study 15735116 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, epirubicin, and cyclophosphamide (FEC)
Number of subjects: 259
Study 12139821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/24 h nitroglycerin patch
Number of subjects: 954
Study 12139821 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/24 h nitroglycerin patch
Number of subjects: 954
Study 12139821 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/24 h nitroglycerin patch
Number of subjects: 954
Study 12139821 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of nitroglycerin patches
Number of subjects: 954
Study 10565799 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine (15-60 mg/day)
Number of subjects: 270
Study 10565799 — intervention group
Group type: COMPARATOR
Intervention: citalopram (20-60 mg/day)
Number of subjects: 270
Study 10565799 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine
Number of subjects: 270
Study 10565799 — intervention group
Group type: COMPARATOR
Intervention: citalopram
Number of subjects: 270
Study 10565799 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine and citalopram
Number of subjects: 270
Study 7881961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lipid intravenous nutrition (75% non-protein calories supplied as lipid)
Number of subjects: 22
Study 7881961 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous glucose intravenous nutrition (100% non-protein calories supplied as glucose)
Number of subjects: 22
Study 2404434 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg IM
Number of subjects: 93
Study 2404434 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg IM
Number of subjects: 93
Study 6776755 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-norgestrel (250 microgram daily) and testosterone oenanthate (200 mg monthly)
Number of subjects: 12
Study 6776755 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-norgestrel (500 microgram daily) and testosterone oenanthate (200 mg monthly)
Number of subjects: 12
Study 6776755 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-norgestrel (250 or 500 microgram daily) and testosterone oenanthate (200 mg monthly)
Number of subjects: 12
Study 6776755 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery phase after treatment
Number of subjects: 12
Study 31532138 — intervention group
Group type: EXPERIMENTAL
Intervention: Otopoint pellet-pressing plus medication (Flunarizine 10 mg twice a day)
Number of subjects: 97
Study 31532138 — intervention group
Group type: COMPARATOR
Intervention: Medication (Flunarizine 10 mg twice a day)
Number of subjects: 97
Study 31532138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 28513876 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized education intervention to reduce restraint and agitation
Number of subjects: 0
Study 26555069 — intervention group
Group type: COMPARATOR
Intervention: cART (efavirenz, tenofovir, and either emtricitabine or lamivudine)
Number of subjects: 62
Study 26555069 — intervention group
Group type: EXPERIMENTAL
Intervention: cART plus integrase inhibitor and CCR5 antagonist (cART+; raltegravir and maraviroc)
Number of subjects: 62
Study 26555069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arms (cART and cART+)
Number of subjects: 62
Study 26555069 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants (cART and cART+)
Number of subjects: 62
Study 23414112 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 30
Study 23414112 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery using an oscillating saw
Number of subjects: 30
Study 21308888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for social phobia
Number of subjects: 24
Study 19438993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg daily for 4 days)
Number of subjects: 6
Study 19438993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 4 days)
Number of subjects: 6
Study 17347181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 15 mg in 3 ml of glucose 5% (hyperbaric)
Number of subjects: 36
Study 17347181 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 15 mg in 3 ml of CSF (isobaric)
Number of subjects: 36
Study 16797292 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict sodium diet (80 to 100 mmol sodium daily)
Number of subjects: 32
Study 16797292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary sodium restriction)
Number of subjects: 32
Study 15012700 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 18
Study 15012700 — intervention group
Group type: COMPARATOR
Intervention: Control (no sertraline)
Number of subjects: 18
Study 10802128 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram infusion (40 mg per day)
Number of subjects: 254
Study 10802128 — intervention group
Group type: COMPARATOR
Intervention: Citalopram tablet (40 mg per day)
Number of subjects: 254
Study 8605459 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blinding in trials
Number of subjects: 110
Study 8605459 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with no exclusions after randomisation
Number of subjects: 110
Study 8605459 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with exclusions
Number of subjects: 110
Study 1839714 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-based anesthetic
Number of subjects: 53
Study 1839714 — intervention group
Group type: COMPARATOR
Intervention: Inhaled anesthetic
Number of subjects: 53
Study 7124302 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 60
Study 7124302 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study 7124302 — intervention group
Group type: COMPARATOR
Intervention: Comparison between local and general anaesthesia
Number of subjects: 60
Study 31779508 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 0
Study 31779508 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) - optimized oral levodopa-carbidopa IR
Number of subjects: 0
Study 31158254 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA detection and genotyping using Anyplex II HPV28 genotyping test
Number of subjects: 253
Study 31158254 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 253
Study 31158254 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil-9 vaccine genotypes
Number of subjects: 253
Study 28068906 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Walk Engage intervention
Number of subjects: 8
Study 28068906 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 8
Study 26519056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 42
Study 26519056 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisodium citrate
Number of subjects: 42
Study 26519056 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 42
Study 22562077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 103
Study 22562077 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 103
Study 22562077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 21209225 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals enriched in monounsaturated fatty acids (MUFAs)
Number of subjects: 14
Study 21209225 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals enriched in saturated fatty acids (SFAs)
Number of subjects: 14
Study 21209225 — intervention group
Group type: COMPARATOR
Intervention: No fat (control)
Number of subjects: 14
Study 19675489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Training (RT; n = 8)
Number of subjects: 15
Study 19675489 — intervention group
Group type: COMPARATOR
Intervention: Detraining (DTR; n = 7)
Number of subjects: 15
Study 17277585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (including leisure-time physical activity, dietary changes, and weight loss)
Number of subjects: 481
Study 17277585 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased total leisure-time physical activity (LTPA)
Number of subjects: 481
Study 17277585 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable dietary changes (using a dietary score)
Number of subjects: 481
Study 17277585 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 481
Study 15511336 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (50-150 mg/day for 5 days)
Number of subjects: 76
Study 15511336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant FSH (daily starting dose 75 IU for up to three consecutive cycles)
Number of subjects: 76
Study 15511336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant FSH
Number of subjects: 76
Study 15511336 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 76
Study 11520383 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based anticoagulation service (ACS)
Number of subjects: 300
Study 11520383 — intervention group
Group type: COMPARATOR
Intervention: Control (no ACS access)
Number of subjects: 300
Study 9750705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 32
Study 9750705 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 32
Study 8174308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate super‐imposed on cyclical hormonal replacement therapy (HRT)
Number of subjects: 0
Study 8174308 — intervention group
Group type: COMPARATOR
Intervention: HRT alone
Number of subjects: 0
Study 3207544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg by mouth 8‐14 h and 50 mg i.m. 90 min before surgery
Number of subjects: 110
Study 3207544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg i.m. 6‐hourly with a single preinduction dose of sodium citrate 0.3 mol litre‐1 (15 or 30 ml)
Number of subjects: 110
Study 3207544 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate 0.3 mol litre‐1 (15 or 30 ml)
Number of subjects: 110
Study 3207544 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate 0.3 mol litre‐1 alone
Number of subjects: 110
Study 31135552 — intervention group
Group type: EXPERIMENTAL
Intervention: Research donation (USD 5 donation to a procedure-specific research program)
Number of subjects: 3000
Study 31135552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient donation (USD 5 donation to provide medical supplies to a pediatric orthopaedic patient)
Number of subjects: 3000
Study 31135552 — intervention group
Group type: COMPARATOR
Intervention: Control (no incentive)
Number of subjects: 3000
Study 31135552 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanation (explanation that response supports quality improvement)
Number of subjects: 3000
Study 28679524 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin treatment for 12 months
Number of subjects: 218
Study 25788006 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate/isotonic saline (MSG/IS) injection in TMJ
Number of subjects: 20
Study 25788006 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate/isotonic saline (MSG/IS) injection in masseter
Number of subjects: 20
Study 25788006 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (IS) injection in masseter
Number of subjects: 20
Study 25788006 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate/isotonic saline (MSG/IS) injection in masseter and TMJ
Number of subjects: 20
Study 25788006 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful masseter injection
Number of subjects: 20
Study 25788006 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful TMJ injection
Number of subjects: 20
Study 23984393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 52
Study 23984393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21822037 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 156
Study 21822037 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 156
Study 21822037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography
Number of subjects: 156
Study 21822037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 156
Study 21822037 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonoscopy
Number of subjects: 156
Study 21822037 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography and endoscopic ultrasound
Number of subjects: 156
Study 19105686 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-tailored information
Number of subjects: 899
Study 19105686 — intervention group
Group type: COMPARATOR
Intervention: General information about breast health (Control)
Number of subjects: 899
Study 17903498 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia with 0.2% ropivacaine containing 2 microg/mL fentanyl
Number of subjects: 40
Study 17903498 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia with morphine
Number of subjects: 40
Study 15526700 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 0
Study 15526700 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-poor plasma (PPP)
Number of subjects: 0
Study 12357520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation with inflation volume of 32 cc
Number of subjects: 82
Study 12357520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation with inflation volume of 40 cc
Number of subjects: 82
Study 12357520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation
Number of subjects: 82
Study 12357520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation with larger inflation volumes
Number of subjects: 82
Study 10531532 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot juice
Number of subjects: 0
Study 10531532 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 7782353 — intervention group
Group type: EXPERIMENTAL
Intervention: Underarm plastic brace
Number of subjects: 286
Study 7782353 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 286
Study 7782353 — intervention group
Group type: COMPARATOR
Intervention: Nighttime surface electrical stimulation
Number of subjects: 286
Study 2145377 — intervention group
Group type: EXPERIMENTAL
Intervention: Human plasminogen
Number of subjects: 500
Study 2145377 — intervention group
Group type: EXPERIMENTAL
Intervention: Human plasmin
Number of subjects: 500
Study 2145377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 2145377 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli endotoxin or oleic acid (in experimental animals)
Number of subjects: 500
Study 734578 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental epidural block with lower dosages of bupivacaine; specific dosage not mentioned; technique involved patients kneeling on all fours.
Number of subjects: 0
Study 734578 — intervention group
Group type: COMPARATOR
Intervention: Standard and modified segmental epidural block; specific dosages and techniques not mentioned.
Number of subjects: 0
Study 30676045 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Warrior Renew treatment (8 sessions)
Number of subjects: 39
Study 31564281 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan combined with Alpha-lipoic Acid (ALA)
Number of subjects: 102
Study 31564281 — intervention group
Group type: COMPARATOR
Intervention: Valsartan alone
Number of subjects: 102
Study 27193583 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-rich diet
Number of subjects: 26
Study 27193583 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 26
Study 25638038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, personalized site (treatment)
Number of subjects: 130
Study 25638038 — intervention group
Group type: COMPARATOR
Intervention: Test-locator condition (control)
Number of subjects: 130
Study 24099353 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cue context (listening to vignettes describing positive drinking scenarios)
Number of subjects: 0
Study 24099353 — intervention group
Group type: COMPARATOR
Intervention: Negative cue context (listening to vignettes describing negative drinking scenarios)
Number of subjects: 0
Study 24099353 — intervention group
Group type: COMPARATOR
Intervention: Less problematic drinkers in either cue condition
Number of subjects: 0
Study 21415073 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 341